A Randomized Single-Blind, Placebo-Controlled, Ascending Single Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Trial Profile

A Randomized Single-Blind, Placebo-Controlled, Ascending Single Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2014

At a glance

  • Drugs SEP 363856 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 04 Apr 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 31 Mar 2014 Planned End Date changed from 1 Jan 2014 to 1 Mar 2014, as per ClinicalTrials.gov record.
    • 31 Mar 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top